UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)

British journal of dermatology (1951), 2020-05, Vol.182 (5), p.1158-1166

2020

Volltextzugriff (PDF)

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

British journal of dermatology (1951), 2015-05, Vol.172 (5), p.1395-1406

2015

Volltextzugriff (PDF)

Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic

British journal of dermatology (1951), 2020-08, Vol.183 (2), p.404-406

2020

Volltextzugriff (PDF)

Ciclosporin in psoriasis clinical practice: an international consensus statement

British journal of dermatology (1951), 2004-05, Vol.150 (s67), p.11-23

2004

Volltextzugriff (PDF)

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.928-938

2017

Volltextzugriff (PDF)

Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases

British journal of dermatology (1951), 2005-09, Vol.153 (3), p.549-551

2005

Volltextzugriff (PDF)

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

British journal of dermatology (1951), 2020-08, Vol.183 (2), p.294-302

2020

Volltextzugriff (PDF)

Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study

British journal of dermatology (1951), 2001-10, Vol.145 (4), p.546-553

2001

Volltextzugriff (PDF)

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study

British journal of dermatology (1951), 2019-05, Vol.180 (5), p.1069-1076

2019

Volltextzugriff (PDF)

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

British journal of dermatology (1951), 2021-12, Vol.185 (6), p.1124-1134

2021

Volltextzugriff (PDF)

Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

British journal of dermatology (1951), 2021-11, Vol.185 (5), p.952-960

2021

Volltextzugriff (PDF)

Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE)

British journal of dermatology (1951), 2020-07, Vol.183 (1), p.60-70

2020

Volltextzugriff (PDF)

Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study

Journal of the European Academy of Dermatology and Venereology, 2021-01, Vol.35 (1), p.123-134

2021

Volltextzugriff (PDF)

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study

British journal of dermatology (1951), 2016-05, Vol.174 (5), p.985-995

2016

Volltextzugriff (PDF)

Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate

Dermatology (Basel), 2005-01, Vol.211 (3), p.256-263

2005

Volltextzugriff (PDF)

A novel, web-based, psychological intervention for people with psoriasis: the electronic Targeted Intervention for Psoriasis (eTIPs) study

British journal of dermatology (1951), 2013-08, Vol.169 (2), p.329-336

2013

Volltextzugriff (PDF)

Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials

Journal of the European Academy of Dermatology and Venereology, 2021-04, Vol.35 (4), p.928-937

2021

Volltextzugriff (PDF)

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis

British journal of dermatology (1951), 2019-12, Vol.181 (6), p.1265-1271

2019

Volltextzugriff (PDF)

Defining trajectories of response in patients with psoriasis treated with biologic therapies

British journal of dermatology (1951), 2021-10, Vol.185 (4), p.825-835

2021

Volltextzugriff (PDF)

Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients

British journal of dermatology (1951), 2014-09, Vol.171 (3), p.485-491

2014

Volltextzugriff (PDF)

Clindamycin and rifampicin combination therapy for hidradenitis suppurativa

British journal of dermatology (1951), 2006-05, Vol.154 (5), p.977-978

2006

Volltextzugriff (PDF)

Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review

British journal of dermatology (1951), 2019-08, Vol.181 (2), p.256-264

2019

Volltextzugriff (PDF)

Identification of factors that may influence the selection of first‐line biological therapy for people with psoriasis: a prospective, multicentre cohort study

British journal of dermatology (1951), 2017-09, Vol.177 (3), p.828-836

2017

Volltextzugriff (PDF)

Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis

British journal of dermatology (1951), 2015-11, Vol.173 (5), p.1271-1273

2015

Volltextzugriff (PDF)

Reaching complete or near‐complete resolution of psoriasis: benefit and risk considerations

British journal of dermatology (1951), 2017-08, Vol.177 (2), p.587-590

2017

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Aktive Filter

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Dermatology
(44)
Humans
(44)
Life Sciences & Biomedicine
(44)
Science & Technology
(44)
Psoriasis - Drug Therapy
(35)
Female
(31)
Male
(30)
Psoriasis
(29)
Adult
(27)
Middle Aged
(27)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Severity Of Illness Index
(18)
Aged
(15)
Psoriasis. Parapsoriasis. Lichen
(15)
Double-Blind Method
(14)
Quality Of Life
(12)
Dermatologic Agents - Therapeutic Use
(11)
Drug Administration Schedule
(10)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(44)
Wiley Online Library
(43)
Wiley Online Library Full Collection 2018
(43)
Journals@Ovid Complete
(43)
Oxford Journals
(41)
Ingenta
(3)

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic

Ciclosporin in psoriasis clinical practice: an international consensus statement

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE)

Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study

Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate

A novel, web-based, psychological intervention for people with psoriasis: the electronic Targeted Intervention for Psoriasis (eTIPs) study

Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis

Defining trajectories of response in patients with psoriasis treated with biologic therapies

Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients

Clindamycin and rifampicin combination therapy for hidradenitis suppurativa

Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review

Identification of factors that may influence the selection of first‐line biological therapy for people with psoriasis: a prospective, multicentre cohort study

Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis

Reaching complete or near‐complete resolution of psoriasis: benefit and risk considerations

Aktive Filter

Suchergebnisse filtern